First National Bank of Omaha Purchases Shares of 81,813 Boston Scientific Corporation $BSX

First National Bank of Omaha acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, HoldingsChannel.com reports. The fund acquired 81,813 shares of the medical equipment provider’s stock, valued at approximately $3,533,000.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Boston Scientific in the second quarter worth $5,534,781,000. Norges Bank acquired a new stake in shares of Boston Scientific in the 4th quarter worth $2,199,395,000. Bank of New York Mellon Corp acquired a new stake in shares of Boston Scientific in the 2nd quarter worth $339,031,000. Deutsche Bank AG purchased a new position in Boston Scientific during the 2nd quarter worth $254,247,000. Finally, Assenagon Asset Management S.A. grew its stake in Boston Scientific by 133.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after buying an additional 5,751,760 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $50.51 on Wednesday. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company’s fifty day moving average price is $46.15 and its 200 day moving average price is $58.50. The company has a market capitalization of $73.20 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the company posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research note on Wednesday, July 29th. Daiwa Securities Group downgraded shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Needham & Company LLC dropped their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Finally, Royal Bank Of Canada cut their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 194,522 shares of company stock worth $9,385,210 over the last quarter. 0.34% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.